Triple Negative Breast Cancer Tnbc clinical trials

Explore recruiting triple negative breast cancer tnbc clinical trials.

Recruiting triple negative breast cancer tnbc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Triple Negative Breast Cancer Tnbc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Czechia, Hungary, Poland, Spain, Germany, Denmark +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combination with abemaciclib (an oral CDK 4/6 inhibitor) in 4 cohorts of locoregionally advanced inoperable or metastatic AR positive triple-negative breast cancer (AR+ TNBC).

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer

France, Sweden, Poland, Spain, Finland, Portugal +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

"neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Triple Negative Breast Cancer Tnbc trials by city

Triple Negative Breast Cancer Tnbc in Toronto Triple Negative Breast Cancer Tnbc in Vancouver Triple Negative Breast Cancer Tnbc in Montreal Triple Negative Breast Cancer Tnbc in Calgary Triple Negative Breast Cancer Tnbc in Edmonton Triple Negative Breast Cancer Tnbc in Ottawa Triple Negative Breast Cancer Tnbc in Winnipeg Triple Negative Breast Cancer Tnbc in Quebec City Triple Negative Breast Cancer Tnbc in Hamilton Triple Negative Breast Cancer Tnbc in Kitchener Triple Negative Breast Cancer Tnbc in London Triple Negative Breast Cancer Tnbc in Halifax Triple Negative Breast Cancer Tnbc in New York Triple Negative Breast Cancer Tnbc in Los Angeles Triple Negative Breast Cancer Tnbc in Chicago Triple Negative Breast Cancer Tnbc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease